Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16337. Online ahead of print.

Stephen E Roberts ¹, Sian Morrison-Rees ¹, Nikhil Thapar ^2 3, Marc A Benninga ⁴, Osvaldo Borrelli ², Ilse Broekaert ⁵, Jernej Dolinsek ⁶, Javier Martin-de-Carpi ⁷, Emmanuel Mas ⁸, Erasmo Miele ⁹, Corina Pienar ¹⁰, Carmen Ribes-Koninckx ¹¹, Rut A Thomassen ¹², Mike Thomson ¹³, Christos Tzivinikos ¹⁴, Kymberley Thorne ¹, Ann John ¹, John G Williams ¹

Author information

• ¹Swansea, UK.
• ²London, UK.
• ³Brisbane, Australia.
• ⁴Amsterdam, The Netherlands.
• ⁵Cologne, Germany.
• ⁶Maribor, Slovenia.
• ⁷Barcelona, Spain.
• ⁸Toulouse, France.
• ⁹Naples, Italy.
• ¹⁰Timisoara, Romania.
• ¹¹Valencia, Spain.
• ¹²Oslo, Norway.
• ¹³Sheffield, UK.
• ¹⁴Dubai, UAE.

Abstract

Background: Coeliac disease is one of the most prevalent immune-mediated gastrointestinal disorders in children.

Aim: To review the incidence and prevalence of paediatric coeliac disease, and their trends, regionally across Europe, overall and according to age at diagnosis.

Methods: Systematic review and meta-analysis from January 1, 1950 to December 31, 2019, based on PubMed, CINAHL and the Cochrane Library, searches of grey literature and websites and hand searching of reference lists. A total of 127 eligible studies were included.

Results: The prevalence of previously undiagnosed coeliac disease from screening surveys (histology based) ranged from 0.10% to 3.03% (median = 0.70%), with a significantly increasing annual trend (P = 0.029). Prevalence since 2000 was significantly higher in northern Europe (1.60%) than in eastern (0.98%), southern (0.69%) and western (0.60%) Europe. Large increases in the incidence of diagnosed coeliac disease across Europe have reached 50 per 100 000 person-years in Scandinavia, Finland and Spain. The median age at diagnosis increased from 1.9 years before 1990 to 7.6 since 2000. Larger increases in incidence were found in older age groups than in infants and ages <5 years.

Conclusions: Paediatric coeliac disease incidence and prevalence have risen across Europe and appear highest in Scandinavia, Finland and Spain. The most recent evidence shows large increases in incidence in most regions, but stabilisation in some (notably Sweden and Finland). Sharp increases in the age at diagnosis may reflect increases in milder and asymptomatic cases diagnosed since reliable serology testing became widely used, through endomysial antibodies after 1990 and tissue transglutaminase antibodies around 2000.